Literature DB >> 9107152

Multisomatoform disorder. An alternative to undifferentiated somatoform disorder for the somatizing patient in primary care.

K Kroenke1, R L Spitzer, F V deGruy, S R Hahn, M Linzer, J B Williams, D Brody, M Davies.   

Abstract

BACKGROUND: For clinical or research use in primary care, the DSM-IV diagnostic criteria for somatization disorder are too restrictive, while the criteria for undifferentiated somatoform disorder are overly inclusive. In this article, we examine the validity of multisomatoform disorder, defined as 3 or more medically unexplained, currently bothersome physical symptoms plus a long (> or = 2 years) history of somatization.
METHODS: Data from the Primary Care Evaluation of Mental Disorders Study of 1000 patients from 4 primary care sites were analyzed. The outcomes assessed were 6 domains of health-related quality of life, using the 20-item Short-Form General Health Survey; self-reported disability days and health care use; satisfaction with care; and physician-rated difficulty of the encounter.
RESULTS: Multisomatoform disorder was diagnosed in 82 (8.2%) of the 1000 patients who were enrolled in the Primary Care Evaluation of Mental Disorders Study. Compared with mood and anxiety disorders, multisomatoform disorder was associated with comparable impairment in health-related quality of life, more self-reported disability days and clinic visits, and greater clinician-perceived patient difficulty.
CONCLUSIONS: Multisomatoform disorder may be a valid diagnosis and potentially more useful than the DSM-IV diagnosis of undifferentiated somatoform disorder. Also, because multisomatoform disorder has a large and independent effect on impairment, its diagnosis should not be precluded simply because of a coexisting mood or anxiety disorder.

Entities:  

Mesh:

Year:  1997        PMID: 9107152     DOI: 10.1001/archpsyc.1997.01830160080011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  62 in total

1.  Somatisation in primary care. Solitary disclosure allows people to determine their own dose.

Authors:  James W Pennebaker
Journal:  BMJ       Date:  2002-03-02

2.  A method for rating charts to identify and classify patients with medically unexplained symptoms.

Authors:  Robert C Smith; Elie Korban; Mohammed Kanj; Robert Haddad; Judith S Lyles; Catherine Lein; Joseph C Gardiner; Annemarie Hodges; Francesca C Dwamena; John Coffey; Clare Collins
Journal:  Psychother Psychosom       Date:  2004 Jan-Feb       Impact factor: 17.659

Review 3.  Use of psychopharmacological agents for functional gastrointestinal disorders.

Authors:  R E Clouse; P J Lustman
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

4.  Should general psychiatry ignore somatization and hypochondriasis?

Authors:  Francis Creed
Journal:  World Psychiatry       Date:  2006-10       Impact factor: 49.548

5.  Medically unexplained physical symptoms.

Authors:  Jeffrey L Jackson; Susan George; Sherri Hinchey
Journal:  J Gen Intern Med       Date:  2009-04       Impact factor: 5.128

Review 6.  Somatoform disorders and medically unexplained symptoms in primary care.

Authors:  Heidemarie Haller; Holger Cramer; Romy Lauche; Gustav Dobos
Journal:  Dtsch Arztebl Int       Date:  2015-04-17       Impact factor: 5.594

Review 7.  Health care utilization and poor reassurance: potential predictors of somatoform disorders.

Authors:  Paul R Puri; Joel E Dimsdale
Journal:  Psychiatr Clin North Am       Date:  2011-09

8.  The outcomes among patients presenting in primary care with a physical symptom at 5 years.

Authors:  Jeffrey L Jackson; Mark Passamonti
Journal:  J Gen Intern Med       Date:  2005-11       Impact factor: 5.128

9.  Diagnostic accuracy of predicting somatization from patients' ICD-9 diagnoses.

Authors:  Robert C Smith; Joseph C Gardiner; Zhehui Luo; Kathryn Rost
Journal:  Psychosom Med       Date:  2009-03-17       Impact factor: 4.312

10.  A randomized trial of treatments for high-utilizing somatizing patients.

Authors:  Arthur J Barsky; David K Ahern; Mark R Bauer; Nyryan Nolido; E John Orav
Journal:  J Gen Intern Med       Date:  2013-03-14       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.